Press Room

AAPS 2018

Start
Sunday, November 04, 2018 - 00:00
End
Wednesday, November 07, 2018 - 00:00
Location: Washington DC, United States
Booth Number: 2309
Spray Drying Development by Design | Hovione

If you would like to discuss with us your projects and to find how Hovione can help, schedule a meeting with us. Adam Neunuebel will be pleased to meet you.

adam-neunuebel-photo

Adam Neunuebel

Head of Business Development

 

HOVIONE POSTERS

Poster name / Presentation Authors / Presenter Poster # and Presenter Presentation  Date / Time
Use of Hot Melt Extrusion for the production of controlled release diclofenac formulation with PLGA/PLA - standard and accelerated IVR methods João Henriques #M1030-07-056 - João Henriques Monday, Nov 5
10:30 – 11:30 
Microfludization for Solubility Enhancement – One Technology Fits All Fonseca, T., Duarte, I., Vicente, J.,
Temtem, M
#M1430-10-075 - Iris Duarte Monday, Nov 5
14:30 – 15:30 
Performance evaluation during process development: different techniques, complementary results Luis Sousa #M1530-07-049 - Luis Sousa Monday, Nov 5
15:30 – 16:30 
Identify your limits: definition of Spray drying Tout based on a novel methodology to measure powder stickiness  Luis Sousa #T1130-07-050 - Luis Sousa Tuesday, Nov 6
11:30 – 12:30 
Laser diffraction analysis of supersaturated solutions and application to screening of amorphous dispersions  Luis Sousa #T1230-07-049 - Luis Sousa Tuesday, Nov 6
12:30 – 13:30 
Effect of Surfactant Level on Properties of Celecoxib Amorphous Solid Dispersion  Fan Meng, Rui Ferreira,
Feng Zhang
#T1330-09-065  Tuesday, Nov 6
13:30 – 14:30 
Miniaturized methodology of polymer screening for spray dried dispersions  Luis Sousa #W0930-07-050 - Luis Sousa Wednesday, Nov 7
9:30 – 10:30 
New formulation screening approach to optimize tablet disintegration profiles based on cloud/precipitation point measurement João Henriques #W1030-13-097 - João Henriques Wednesday, Nov 7
10:30 – 11:30 
How to develop an amorphous solid dispersion in tablets with less than 30 g API João Henriques #W1030-13-100 - João Henriques Wednesday, Nov 7
10:30 – 11:30 
DPI Carrier-Based Formulation Scale-Up: A Statistical Analysis Approach Marcio Temtem, Filipa Maia,
Isabel Lopes, Luis Sousa,
Maria Braga, Nuno Neves
#W1230-09-068 - Eunice Costa  Wednesday, Nov 7
12:30 – 13:30 
Simulating the Pulmonary Route: From Actuation to Absoption Beatriz Fernandes, Maria Malmlof,
Marcio Temtem,
M. Luisa Corvo,
Per Gerde, Eunice Costa
#W1230-09-065  Wednesday, Nov 7
12:30 – 13:30 
Molecular Interactions between Rafoxanide and Povidone for Amorphous Solid Dispersion Preparation and Feng Zhang. Fan Meng, Zhifeng Jing,
Yongchao Su, Rui Ferreira, Pengyu Ren 
   

 

 

 

 

 

 

 

 

 

 

 

 

 

You might be also interested in

 

 

Also in the Press Room

See All

Continuous Tableting (CT) is defined as continuous manufacturing of oral dose drugs, specifically tablets. As per ICH's Q13 definition1, a continuous manufacturing process in the pharmaceutical industry comprises at least two unit operations integrated from a mechanical and software perspective. There is a wide combination of possible CT process configurations that are dependent on the needs of the intended product formulation and each of the individual unit operations that constitute the process train can be continuous, semi-continuous, or batch processes. The typical manufacturing processes for tablet formulation are direct compression (DC), dry granulation (DG) and wet granulation (WG)2 - details on these manufacturing processes are beyond the scope of this article, so the interested reader is directed to relevant literature. The actual implementation of CT technology in a facility can broadly vary depending on the level of desired integration and automation. Process trains can be designed to be flexible and converted between multiple configurations (e.g. continuous DC, DG and WG), controlled by the end user from one single software and within a single clean room. The other possibility would be for subsections of the CT process to be divided into multiple clean rooms where inprocess materials are transferred between suites via a bin-to-bin approach (e.g. a granulation suite to prepare granules from raw materials followed by continuous DC (CDC) to blend the granules and produce tablets). The level of automation and instrumentation designed into the CT process (typically involving Process Analytical Technologies, PAT) can open the possibility to implement sophisticated control strategies. Key components of a control strategy that need to be considered for CT are material tracking and genealogy, knowledge of the residence time distribution (RTD), and in-process controls (spectroscopic and/or soft sensors based on process parameters). Holistically, these control strategy elements enable the implementation of a material diversion strategy to automatically divert out of specification material from the process. In their most advanced form, control strategies may also enable real time release testing (RTRt) of the final tablet drug product and reduce the off-line analytical burden and the number of operators needed to manage the process.   Read the full article at gmp-journal.com  

Article

Continuous Tableting and the Road to Global Adoption

Mar 04, 2024